Immucell Corp /de/ ICCC US Equity
Immucell Corp /de/ (Nasdaq: ICCC), an SEC filer in In Vitro & In Vivo Diagnostic Substances, closed at $9.94, -0.8%, on 2026-08-28, with a market cap of $91M as of 2026-08-27, a return on equity of -3.8%, a net margin of -3.8% and 3-year sales growth of 14.2%. Institutional ownership, earnings history and filed financials are on the tabs below.
Legal & controls
Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”
| Fiscal year | Filed | Item 3 | ICFR | disclosure controls | material weakness | Filing |
|---|---|---|---|---|---|---|
| 2025-12-31 | 2026-03-30 | described here | not extracted | effective | none in Item 9A | EDGAR |
Item 3 · In the ordinary course of business, we may become subject to periodic lawsuits, investigations and claims. Although we cannot predict with certainty the ultimate resolution of any such lawsuits, investigations and claims against us, we do not believe that any pending or threatened legal proceedings to which we are or could become a party will have a material adverse effect on our business, results of operations, or financial condition. Item 9A · disclosure controls · Based on this evaluation, those officers concluded that our disclosure controls and procedures were effective as of that date. | ||||||
| 2024-12-31 | 2025-03-28 | described here | not extracted | effective | none in Item 9A | EDGAR |
Item 3 · — LEGAL PROCEEDINGS In the ordinary course of business, we may become subject to periodic lawsuits, investigations and claims. Although we cannot predict with certainty the ultimate resolution of any such lawsuits, investigations and claims against us, we do not believe that any pending or threatened legal proceedings to which we are or could become a party will have a material adverse effect on our business, results of operations, or financial condition. Item 9A · disclosure controls · Based on this evaluation, that officer concluded that our disclosure controls and procedures were effective as of that date. | ||||||
| 2023-12-31 | 2024-04-01 | described here | not extracted | not extracted | disclosed | EDGAR |
Item 3 · In the ordinary course of business, we may become subject to periodic lawsuits, investigations and claims. Although we cannot predict with certainty the ultimate resolution of any such lawsuits, investigations and claims against us, we do not believe that any pending or threatened legal proceedings to which we are or could become a party will have a material adverse effect on our business, results of operations, or financial condition. Item 9A · ICFR · Based on our assessment for the fourth quarter of 2023, we have concluded that our internal controls over financial reporting were effective as of December 31, 2023. Item 9A · disclosure controls · Based on this evaluation, that officer concluded that our disclosure controls and procedures were effective as of that date. Item 9A · material weakness · Material Weaknesses in Internal Controls Over Financial Reporting: Management assesses the effectiveness of the Company’s internal control over financial reporting at the end of each quarter. | ||||||
| 2022-12-31 | 2023-03-29 | described here | not extracted | not extracted | disclosed | EDGAR |
Item 3 · In the ordinary course of business, we may become subject to periodic lawsuits, investigations and claims. Although we cannot predict with certainty the ultimate resolution of any such lawsuits, investigations and claims against us, we do not believe that any pending or threatened legal proceedings to which we are or could become a party will have a material adverse effect on our business, results of operations, or financial condition. Item 9A · ICFR · Based on this assessment, we concluded that our internal control over financial reporting was not effective as of September 30, 2022, June 30, 2022 and March 31, 2022, because we identified one material weakness in the operation (but not the design) of our internal controls over financial reporting during the first quarter of 2022 and a second one during the third quarter of 2022. Item 9A · disclosure controls · Based on this evaluation, that officer concluded that our disclosure controls and procedures were effective as of that date. Item 9A · material weakness · Material Weakness in Internal Controls over Financial Reporting: Management assesses the effectiveness of the Company’s internal control over financial reporting at the end of each quarter. | ||||||
| 2021-12-31 | 2022-03-30 | described here | effective | effective | none in Item 9A | EDGAR |
Item 3 · In the ordinary course of business, we may become subject to periodic lawsuits, investigations and claims. Although we cannot predict with certainty the ultimate resolution of any such lawsuits, investigations and claims against us, we do not believe that any pending or threatened legal proceedings to which we are or could become a party will have a material adverse effect on our business, results of operations, or financial condition. Item 9A · ICFR · Based on management’s assessment, we believe that our internal control over financial reporting was effective as of December 31, 2021. Item 9A · disclosure controls · Based on this evaluation, that officer concluded that our disclosure controls and procedures were effective as of that date. | ||||||
5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.
- Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
- A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
- An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
- When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
- Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.